Skip to main content

How is Trogarzo used in the treatment of HIV?

Medically reviewed by Drugs.com. Last updated on Sep 28, 2023.

Official answer

by Drugs.com

Trogarzo (ibalizumab-uiyk) is used to treat the small percentage of patients who have multidrug-resistant human immunodeficiency virus type 1 HIV (MDR HIV-1 Infection) and who have failed other HIV therapies.

Trogarzo is a first-in-class CD4-directed post-attachment HIV-1 inhibitor that works by binding to CD4+ receptors on host cells and blocking the HIV virus from infecting the cells. It is the first monoclonal antibody approved for the treatment of MDR HIV-1 infection, and is used in combination with other antiretroviral drugs.

Trogarzo is administered intravenously (IV) once every 14 days by a trained medical professional.

Read next

Three real-life patients feature in the Dovato commercial “Detect This” released on May 23, 2022. They are Jovon [surname withheld], Ann Edwards, and Armando [surname withheld]. Continue reading

  • Biktarvy is a complete regimen and use with other antiretroviral medications for the treatment of HIV-1 infection is not recommended.
  • Biktarvy is associated with many drug interactions as it contains three different medicines, increasing your risk for interactions. Have your health care provider check for possible interactions with other prescription medicines, OTCs or herbal you take.
  • You should not take Biktarvy with dofetilide (Tikosyn), a drug used for heart rhythm disorders or rifampin (Rifadin), a medicine for tuberculosis (TB). These drugs are contraindicated with the use of Biktarvy.
Continue reading

If you miss one dose of Biktarvy (bictegravir, tenofovir, and emtricitabine), take the missed dose as soon as you remember it. If it is almost time for your next dose, just skip the missed dose and take your next dose at the regular time. Try not to miss doses. Taking your medicine as prescribed will help you to keep your HIV under control and help prevent drug resistance. Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer